Hybrid immune cells, culture systems and in vitro culture methods thereof
By designing a hybrid immune cell culture system containing activation and amplification media, and combining activation methods with bisphosphonates and biological response modifiers, highly efficient amplification of hybrid immune cells was achieved. This solved the problems of unstable amplification efficiency and low purity in existing technologies, and obtained a high proportion of γδT cells and NK cells with strong cytotoxicity and high amplification fold.
Patent Information
- Application Number
- CN202511794201.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-02
- Publication Date
- 2026-03-27
- Estimated Expiration
- 2045-12-02
AI Technical Summary
In existing technologies, the in vitro expansion efficiency of mixed immune cells is unstable, the expected cell purity ratio is low, and the production process is difficult to standardize. It is difficult to efficiently expand a mixed immune cell system with a high proportion of γδT cells and a certain proportion of NK cells and NKT cells in about 20 days.
A mixed immune cell culture system containing activation medium, immune cell initial activation components, and expansion medium was adopted. The activation medium included cell basal medium, serum substitute UltraGro, and cytokines. Human recombinant IL2 and IL15 were added to the expansion medium. The cells were activated by a combination of bisphosphonates and biological response modifiers, and coated with soluble antibodies to achieve continuous activation and expansion of cells.
It achieves efficient expansion of mixed immune cells with a stable cell type ratio: 75%~80% γδT cells, 10%~15% NK cells, and 1%~2% NKT cells. The expansion fold can reach 2000-8000 times, with high cell viability and strong cytotoxicity. It also reduces culture costs and has broad clinical application prospects.